Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Accuray's CyberKnife G4 System Receives Shonin Approval

August 3, 2010 6:35 am | by Bio-Medicine.Org | News | Comments

SUNNYVALE, Calif. , Aug. 3 /- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the CyberKnife® G4 Robotic Radiosurgery System to...

TOPICS:

Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity

August 3, 2010 6:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO , Aug. 3 /- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) announced the online publication of results from its COR-BMOD trial of Contrave® (naltrexone SR/bupropion SR) in the journal Obesity . The COR-BMOD trial evaluated intensive behavior modification (BMOD) plus...

TOPICS:

Volcano Corporation Presentation at Canaccord Genuity Growth Conference to be Webcast

August 3, 2010 6:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO , Aug. 3 /- Volcano Corporation (Nasdaq: VOLC ), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the...

TOPICS:
Advertisement

Sirona Dental 3Q net income falls 19 percent

August 3, 2010 5:45 am | by The Associated Press | News | Comments

Dental equipment maker Sirona Dental Systems Inc. said Tuesday its fiscal third-quarter net income fell 19 percent on higher expenses.The company reported net income of $16.6 million, or 29 cents per share, for the three months ended June 30, down from $20.5 million, or 37 cents per share, a...

Genzyme reportedly in buyout talks with Sanofi

August 3, 2010 5:36 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Genzyme Corp. and French drug maker Sanofi-Aventis are in talks over a possible sale, according to several reports. The news comes after weeks of speculation, prompted first by comments from Sanofi CEO Chris Viehbacher that it was in the market to buy a company worth about $20 billion.

FDA Summary of Safety and Effectiveness Data (SSED) Clinical Section Checklist

August 3, 2010 5:31 am | by U.S. Food & Drug Administration | News | Comments

The Summary of Safety and Effectiveness (SSED) is a document mandated by the Food, Drug and Cosmetic Act subparagraph 520(h)(1)(A) to be publicly available upon issuance of an approval order of a premarket approval application (PMA).

TOPICS:

Federal Register: Medical Device User Fee Rates for Fiscal Year 2011

August 3, 2010 5:31 am | by U.S. Food & Drug Administration | News | Comments

The FDA is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2011. The Federal Food, Drug, and Cosmetic Act (the act), as amended by the Medical Device User Fee Amendments of 2007 (title II of the Food and..

TOPICS:

AACR to Ring Opening Bell at NASDAQ Stock Market

August 3, 2010 4:35 am | by AACR | News | Comments

PHILADELPHIA – The American Association for Cancer Research's Chief Executive Officer, Margaret Foti, Ph.D., M.D. (h.c.), along with other AACR representatives, will ring the opening bell at the NASDAQ Stock Market on Tuesday, August 3, signaling the start of the day's trading. The...

TOPICS:
Advertisement

China Pharma Holdings, Inc. to Report Second Quarter 2010 Financial Results on August 10, 2010

August 3, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

HAIKOU CITY, China , Aug. 3 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI ), which develops, manufactures, and markets specialty pharmaceutical products in China , today announced that it plans to release its second quarter 2010 financial...

TOPICS:

Boston Scientific Begins Clinical Trial Enrollment for New Coronary Stent with Bioabsorbable Polymer and Everolimus Drug Coating

August 3, 2010 4:35 am | by Boston Scientific | News | Comments

EVOLVE trial to evaluate Company's fourth-generation SYNERGY™ drug-eluting coronary stent

TOPICS:

Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010

August 3, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

BEIJING , Aug. 3 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical") (NYSE: CCM ), operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it will report its unaudited financial results for the...

TOPICS:

Dotted Eyes releases Contractor Portal v2.0 – the Definitive Data Sharing Platform

August 3, 2010 2:36 am | by RealWire | News | Comments

Shared access to asset data and aerial imagery sets the bar for 'data sharing without frontiers' in the new climate of local government collaborationBirmingham, 03 August 2010 - Dotted Eyes, the market leading GeoData and information software specialists, today announces the release of...

TOPICS:

News briefs from the August issue of Chest

August 2, 2010 9:33 pm | by EurekAlert | News | Comments

(American College of Chest Physicians) News briefs from the August issue of Chest discuss how diabetes may reduce lung function; how aerobic activity helps improve asthma symptoms; and how home sleep testing may be a viable option.

TOPICS:

For Eyes Optical Takes Man to Places He's Never Been Before in Humorous New TV Campaign

August 2, 2010 7:36 pm | by Bio-Medicine.Org | News | Comments

NEW YORK , Aug. 2 /- As eyewear is increasingly being marketed as a beauty and fashion product, For Eyes Optical rolls out a series of new television commercials for those who have lost sight of the fact that there's no need to pay for illusions that glasses can't deliver. Using the...

TOPICS:

DaVita 2Q profit rises as business expands

August 2, 2010 1:45 pm | by The Associated Press | News | Comments

Kidney dialysis services provider DaVita Inc. said Monday its net income edged up 2 percent in the second quarter as it expanded and provided more treatments.DaVita said its earnings rose to $107.9 million, or $1.04 per share, from $105.8 million, or $1.02 per share, a year ago. The latest...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading